Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Balance Sheet: Assets 
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Pfizer Inc., consolidated balance sheet: assets (quarterly data)

US$ in millions

Microsoft Excel
Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Cash and cash equivalents 1,043 1,092 1,052 719 2,853 3,148 2,632 2,166 416 1,298 1,780 2,470 1,944 1,966 2,372 1,768 1,784 1,587 1,801 2,151
Short-term investments 19,434 8,860 6,048 11,209 9,837 41,033 42,153 17,806 22,316 34,825 31,524 21,427 29,125 27,730 19,328 11,899 10,437 8,912 9,581 8,199
Restricted short-term investments 11,413 11,412
Trade accounts receivable, less allowance for doubtful accounts 11,463 14,451 11,393 10,989 11,177 11,086 10,231 12,305 10,952 16,076 15,155 13,225 11,479 11,897 10,587 9,864 7,930 10,012 9,128 9,881
Inventories 10,851 11,721 11,447 10,892 10,189 10,204 10,310 9,541 8,981 9,513 10,454 9,979 9,059 8,640 8,948 8,493 8,046 9,295 8,564 8,423
Current tax assets 3,314 3,243 3,694 4,233 3,978 3,917 3,194 3,140 3,577 2,544 2,583 3,117 4,266 3,877 3,761 3,419 3,264 4,000 3,426 3,346
Other current assets 4,253 3,856 4,191 4,373 5,299 4,624 4,827 5,120 5,017 6,147 5,970 4,202 3,820 3,790 3,818 4,090 3,606 2,520 2,512 2,738
Current assets 50,358 43,223 37,825 42,415 43,333 74,012 73,347 50,078 51,259 70,403 67,466 54,420 59,693 57,900 48,814 39,533 35,067 47,739 46,424 34,738
Equity-method investments 217 8,582 8,029 8,123 11,637 11,025 11,422 11,175 11,033 9,826 14,799 15,995 16,472 16,349 16,608 16,532 16,856 15,949 15,578 15,524
Long-term investments 2,010 2,180 3,119 3,490 3,731 3,214 3,644 3,568 4,036 4,062 4,163 4,742 5,054 5,248 4,334 3,696 3,406 3,059 3,142 2,696
Property, plant and equipment, less accumulated depreciation 18,393 18,541 18,957 18,803 18,940 17,862 17,488 17,052 16,274 15,441 15,244 15,109 14,882 14,436 14,224 14,011 13,900 14,403 14,113 14,040
Identifiable intangible assets 55,411 59,986 61,240 62,829 64,900 40,224 41,406 42,002 43,370 28,151 29,065 29,816 25,146 26,306 27,323 27,974 28,471 30,927 33,541 34,464
Goodwill 68,527 68,570 68,445 69,297 67,783 51,527 51,572 51,476 51,375 48,441 49,891 50,211 49,208 49,489 49,867 49,791 49,577 59,902 58,449 58,502
Noncurrent deferred tax assets and other noncurrent tax assets 8,662 7,909 7,867 4,942 3,706 8,350 8,261 7,302 6,693 7,136 7,002 5,668 3,341 2,755 2,694 2,537 2,383 2,649 2,360 2,207
Other noncurrent assets 9,818 10,485 10,711 11,196 12,471 8,807 13,028 12,964 13,165 10,890 7,660 7,880 7,680 6,705 6,056 4,744 4,569 4,355 4,327 4,165
Noncurrent assets 163,038 176,253 178,368 178,680 183,168 141,009 146,821 145,539 145,946 123,947 127,824 129,421 121,783 121,288 121,106 119,285 119,162 131,244 131,510 131,598
Total assets 213,396 219,476 216,193 221,095 226,501 215,021 220,168 195,617 197,205 194,350 195,290 183,841 181,476 179,188 169,920 158,818 154,229 178,983 177,934 166,336

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Pfizer Inc. current assets increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Property, plant and equipment, less accumulated depreciation Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Pfizer Inc. property, plant and equipment, less accumulated depreciation decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Pfizer Inc. noncurrent assets decreased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Pfizer Inc. total assets increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Pfizer Inc. cash and cash equivalents increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.
Short-term investments Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. Pfizer Inc. short-term investments increased from Q2 2024 to Q3 2024 and from Q3 2024 to Q4 2024.
Trade accounts receivable, less allowance for doubtful accounts Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Pfizer Inc. trade accounts receivable, less allowance for doubtful accounts increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024 not reaching Q2 2024 level.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Pfizer Inc. inventories increased from Q2 2024 to Q3 2024 but then decreased significantly from Q3 2024 to Q4 2024.